377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINYBreast (DB)-01,-02, and-03 - Hurvitz, S; Modi, S; Li, W (Ann Oncol, 2023)
et al.